NeoStem, Inc. has received a drug manufacturing license following a successful review of its Irvine, CA cGMP facility by the State of California’s Department of Public Health, Food and Drug Branch. NeoStem will produce eltrapuldencel-T (also known as NBS20) from this facility, including the manufacture of eltrapuldencel-T for clinical trial use. Eltrapuldencel-T is the company’s patient-specific targeted cancer immunotherapy under investigation for the treatment of Stage IV or recurr...